Source and scope
This summary is bounded to the recommendations, population and decisions covered by Canadian guideline for Parkinson disease. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CMAJ Parkinson
Source-attributed clinical priorities
- Refer suspected parkinsonism for specialist confirmation because mimics and atypical features change management.
- Individualize symptomatic therapy to motor and nonmotor burden, function, cognition, age and patient priorities.
- Avoid abrupt withdrawal of dopaminergic medicines and reconcile exact timing during every care transition.
- Record nonmotor symptoms such as orthostasis, constipation, sleep, mood and cognition alongside motor findings.
sources for this section:CMAJ Parkinson
Practical assessment and management workflow
1
Document bradykinesia, rigidity, tremor, gait, falls, autonomic features and atypical early red flags.
2
Reconcile exact drug names, formulations and administration times, including relation to meals.
3
Adjust therapy against wearing-off, dyskinesia, hallucinations, sleepiness and functional priorities with specialist input.
4
Coordinate physiotherapy, speech and swallowing, occupational care and advance planning as needs evolve.
sources for this section:CMAJ Parkinson
Safety, red flags and urgent escalation
- Never omit or abruptly stop dopaminergic therapy during hospital admission unless a specialist directs it.
- Escalate aspiration, recurrent falls, delirium, severe orthostasis or sudden inability to move.
- Avoid dopamine-blocking antiemetics and antipsychotics that can markedly worsen parkinsonism.
sources for this section:CMAJ Parkinson
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CMAJ Parkinson
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CMAJ Parkinson
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Medical Association JournalCanadian guideline for Parkinson diseaseaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.